2020, Volume 6, Issue 10
Engineering >> 2020, Volume 6, Issue 10 doi: 10.1016/j.eng.2020.05.017
Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with SARS-CoV-2: A Retrospective Study
a The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China
b Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China & Key Unit of Modulating Liver to Treat Hyperlipemia SATCM & Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China
c The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510120, China
d The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510120, China
e School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510006, China
# These authors contributed equally to this work.
Next Previous
Abstract
Diabetes and its related metabolic disorders have been reported as the leading comorbidities in patients with coronavirus disease 2019 (COVID-19). This clinical study aims to investigate the clinical features, radiographic and laboratory tests, complications, treatments, and clinical outcomes in COVID-19 patients with or without diabetes. This retrospective study included 208 hospitalized patients (≥ 45 years old) with laboratory-confirmed COVID-19 during the period between 12 January and 25 March 2020. Information from the medical record, including clinical features, radiographic and laboratory tests, complications, treatments, and clinical outcomes, were extracted for the analysis. 96 (46.2%) patients had comorbidity with type 2 diabetes. In COVID-19 patients with type 2 diabetes, the coexistence of hypertension (58.3% vs 31.2%), coronary heart disease (17.1% vs 8.0%), and chronic kidney diseases (6.2% vs 0%) was significantly higher than in COVID-19 patients without type 2 diabetes. The frequency and degree of abnormalities in computed tomography (CT) chest scans in COVID-19 patients with type 2 diabetes were markedly increased, including ground-glass opacity (85.6% vs 64.9%, P < 0.001) and bilateral patchy shadowing (76.7% vs 37.8%, P < 0.001). In addition, the levels of blood glucose (7.23 mmol·L‒1 (interquartile range (IQR): 5.80–9.29) vs 5.46 mmol·L‒1 (IQR: 5.00–6.46)), blood low-density lipoprotein cholesterol (LDL-C) (2.21 mmol·L‒1 (IQR: 1.67–2.76) vs 1.75 mmol·L‒1 (IQR: 1.27–2.01)), and systolic pressure (130 mmHg (IQR: 120–142) vs 122 mmHg (IQR: 110–137)) (1 mmHg = 133.3 Pa) in COVID-19 patients with diabetes were significantly higher than in patients without diabetes (P < 0.001). The coexistence of type 2 diabetes and other metabolic disorders is common in patients with COVID-19, which may potentiate the morbidity and aggravate COVID-19 progression. Optimal management of the metabolic hemostasis of glucose and lipids is the key to ensuring better clinical outcomes. Increased clinical vigilance is warranted for COVID-19 patients with diabetes and other metabolic diseases that are fundamental and chronic conditions.
Keywords
COVID-19 ; Coronavirus disease ; Diabetes ; Clinical characteristics ; Comorbidities
References
[ 1 ] Coronavirus disease (COVID-2019) situation reports [Internet]. Geneva: World Health Organization; c2020 [cited 7 April 2020]. Available from: https://www. who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. link1
[ 2 ] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13. link1
[ 3 ] Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acad Radiol 2020;27(5):603–8. link1
[ 4 ] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. link1
[ 5 ] Morbidity and mortality weekly report: novel coronavirus reports [Internet]. Atlanta: Centers for Disease Control and Prevention of US Department of Health & Human Sevices; [updated 2020 May 14; cited 14 May 2020]. Available from: https://www.cdc.gov/mmwr/Novel_Coronavirus_Reports.html. link1
[ 6 ] Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):2000547.
[ 7 ] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. link1
[ 8 ] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020;5 (7):831–40.
[ 9 ] Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020;9(2):575. link1
[10] Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol 2020;30:e2103. link1
[11] Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, VillamizarPeña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623. link1
[12] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. link1
[13] Chinese Diabetes Society. Management suggestions for patients with diabetes and novel coronavirus pneumonia. Chin J Diabetes Mellitus 2020;12(2):73–5. Chinese.
[14] Ma W, Ran X. The management of blood glucose should be emphasized in the treatment of COVID-19. J Sichuan Univ Med Sci Ed 2020;51(2):146–50. link1
[15] Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and metaanalysis. 2020. medRxiv:2020.03.25.20043133.
[16] Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition). Chin J Pract Intern Med 2018;38: 292–44.
[17] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020;36 (7):e3319.
[18] Means C. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy. Metabolism 2020;108:154254. link1
[19] Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116(10)1688–99.
[20] American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care 2020;43(Suppl 1):S3.
[21] Yel L. Selective IgA deficiency. J Clin Immunol 2010;30(1):6–10. link1
[22] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):1–11.
[23] Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest 2020;43:1141–7.
[24] Guo J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. Chin J Integr Med 2017;23(6):403–9. link1
[25] Ye DW, Rong XL, Xu AM, Guo J. Liver-adipose tissue crosstalk: a key player in the pathogenesis of glucolipid metabolic disease. Chin J Integr Med 2017;23 (6):410–4. link1
[26] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020;8 (5):475–81. link1
[27] Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75 (7):1730–41.
[28] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13(9): 752–61. link1
[29] Alqahtani FY, Aleanizy FS, El Hadi A, Mohamed R, Alanazi MS, Mohamed N, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2018;147:e35. link1
[30] Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 2006;23(6):623–8. link1
[31] Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193–9. link1
[32] Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF diabetes atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract 2019;157:107840. link1
京公网安备 11010502051620号
